LWM
ARCT icon

Liberty Wealth Management’s Arcturus Therapeutics ARCT Stock Holding History

Liberty Wealth Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-400
Closed -$19K – 219
2021
Q3 		$19K Hold
400
– – 0.01% 650
2021
Q2 		$14K Hold
400
– – 0.01% 575
2021
Q1 		$32K Hold
400
– – 0.02% 367
2020
Q4 		$32K Buy
+400
New +$27.1K 0.02% 364

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Liberty Wealth Management's ARCT Position: Q4 2021 in Review

Liberty Wealth Management sold out of Arcturus Therapeutics (ARCT) in Q4 2021, closing a stake of 400 shares — an estimated $19K sold.

Liberty Wealth Management first reported a position in ARCT in Q4 2020 and held it in 4 quarters. The position peaked at $32K in Q1 2021. 139 funds tracked by Wall St. Rank hold ARCT as of Q4 2021.

  • Liberty Wealth Management reported no remaining Arcturus Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Liberty Wealth Management sold 400 Arcturus Therapeutics shares in Q4 2021, an estimated $19K.
  • Liberty Wealth Management first reported a position in Arcturus Therapeutics in Q4 2020 and held it in 4 quarters.
  • Liberty Wealth Management's Arcturus Therapeutics position peaked at $32K in Q1 2021.
  • 139 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2021.

Based on Liberty Wealth Management's 13F filing for Q4 2021, filed 15 Feb 2022.